In the latest trading session, 0.59 million Calidi Biotherapeutics Inc (AMEX:CLDI) shares changed hands as the company’s beta touched 1.10. With the company’s most recent per share price at $1.35 changed hands at -$0.06 or -4.61% at last look, the market valuation stands at $25.35M. CLDI’s current price is a discount, trading about -1151.85% off its 52-week high of $16.90. The share price had its 52-week low at $0.73, which suggests the last value was 45.93% up since then. When we look at Calidi Biotherapeutics Inc’s average trading volume, we note the 10-day average is 1.0 million shares, with the 3-month average coming to 1.56 million.
Calidi Biotherapeutics Inc (AMEX:CLDI) trade information
Instantly CLDI was in red as seen in intraday trades today. With action -22.25%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -91.09%, with the 5-day performance at -22.25% in the red. However, in the 30-day time frame, Calidi Biotherapeutics Inc (AMEX:CLDI) is -37.15% down. Looking at the short shares, we see there were 0.59 million shares sold at short interest cover period of 0.88 days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The consensus price target for the stock as assigned by Wall Street analysts is 5.5, meaning bulls need an upside of 75.45% from its recent market value. According to analyst projections, CLDI’s forecast low is 2 with 9 as the target high. To hit the forecast high, the stock’s price needs a -566.67% plunge from its current level, while the stock would need to soar -48.15% for it to hit the projected low.
Calidi Biotherapeutics Inc (CLDI) estimates and forecasts
Data shows that the Calidi Biotherapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -32.07% over the past 6 months, a 74.10% in annual growth rate that is considerably higher than the industry average of 16.70%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
The 2024 estimates are for Calidi Biotherapeutics Inc earnings to increase by 78.64%.
CLDI Dividends
Calidi Biotherapeutics Inc is expected to release its next quarterly earnings report in January.
Calidi Biotherapeutics Inc (AMEX:CLDI)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 18.16% of Calidi Biotherapeutics Inc shares while 2.71% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 3.31%.
Among Mutual Funds, the top two as of Oct 31, 2024 were Fidelity Extended Market Index Fund and Bridgeway Funds Inc-Ultra Small Company Market Fund. With 31.17 shares estimated at $41453.0 under it, the former controlled 0.15% of total outstanding shares. On the other hand, Bridgeway Funds Inc-Ultra Small Company Market Fund held about 0.05% of the shares, roughly 10.0 shares worth around $13301.0.
